Most Read Articles
06 Oct 2018
Supplementation with resistant starch for 12 weeks decreases the inflammatory marker tumour necrosis factor [TNF]-α and heart rate but does not significantly improve glycaemic control and other cardiovascular disease risk factors in prediabetic adults, suggests a study.
6 days ago
Use of the feminizing hormone therapy medroxyprogesterone acetate (MPA) results in minimal side effects, unchanged oestradiol levels and a decline in testosterone in a cohort of transwomen, a study has found.
29 Sep 2019
The duration and degree of overweight in adulthood appear to have lasting influence on breast and colorectal cancer survival, a study has found.
22 Jul 2019
The risk of diabetes mellitus is higher among postmenopausal women who develop primary breast cancer, reports a new study.

Product Highlight - Forxiga

29 Mar 2019
Forxiga provides early cardiorenal benefits beyond HbA1c in a broad type 2 diabetes patient population
• Superior HbA1c reduction vs DPP4i1-2
• Well-established safety profile with no imbalance of AEs* vs placebo3-5
• Early cardiorenal benefits beyond HbA1C in a broad T2DM patients population6

*AEs included are amputations, fractures, bladder cancer or Fournier’s gangrene
Disclaimer: Forxiga is not indicated to reduce the risk of CV events, CV death or hospitalisation for heart failure or for the treatment of CKD

References:
1. Bailey CJ, Gross JL, Pieters A, Bastein A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo- controlled trial. Lancet. 2010;375(9733):2223-2233.                 
2. Rosenstock J, Mathieu C, Chen H, et al. Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin. Arch Endocrinol Metab. 2018;62(4):424-430
3. Data on file. Atlas Approval ID: 801,453.011. AstraZeneca Pharmaceuticals Ltd.
4. FORXIGA Malaysia Prescribing Information (Doc ID-002317198, Version 13.0). April 2018
5. Jabbour S, Seufert J, Scheen A, Karup C, Langkilde AM. The incidence of amputation in the dapagliflozin clinical trial program. Endoc Pract. 2017;23(1):46A.
6. Wiviott SD, Raz I, Bonaca MP, et al. Dapaglifozin and cardiovascular outcomes in type-2 diabetes. N Engl J Med. 2018. doi: 10.1056/NEJMoa1812389

Further information is available in section 11b and in mims.com.
Full prescribing information is available upon request.


Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
06 Oct 2018
Supplementation with resistant starch for 12 weeks decreases the inflammatory marker tumour necrosis factor [TNF]-α and heart rate but does not significantly improve glycaemic control and other cardiovascular disease risk factors in prediabetic adults, suggests a study.
6 days ago
Use of the feminizing hormone therapy medroxyprogesterone acetate (MPA) results in minimal side effects, unchanged oestradiol levels and a decline in testosterone in a cohort of transwomen, a study has found.
29 Sep 2019
The duration and degree of overweight in adulthood appear to have lasting influence on breast and colorectal cancer survival, a study has found.
22 Jul 2019
The risk of diabetes mellitus is higher among postmenopausal women who develop primary breast cancer, reports a new study.